Pennant Investors’s 89bio ETNB Stock Holding History

Pennant Investors’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-44,500	Closed	-$356K	–	29
2024 Q2	$356K	Hold	44,500	–	–	0.09%	28
2024 Q1	$518K	Hold	44,500	–	–	0.13%	22
2023 Q4	$497K	Buy	+44,500	New	+$409K	0.11%	21

Other funds holding ETNB

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Pennant Investors's ETNB Position: Q3 2024 in Review

Pennant Investors sold out of 89bio (ETNB) in Q3 2024, closing a stake of 44,500 shares — an estimated $356K sold.

Pennant Investors first reported a position in ETNB in Q4 2023 and held it in 3 quarters. The position peaked at $518K in Q1 2024. 144 funds tracked by Wall St. Rank hold ETNB as of Q3 2024.

Pennant Investors reported no remaining 89bio position as of Q3 2024 after selling out during the quarter.
Pennant Investors sold 44,500 89bio shares in Q3 2024, an estimated $356K.
Pennant Investors first reported a position in 89bio in Q4 2023 and held it in 3 quarters.
Pennant Investors's 89bio position peaked at $518K in Q1 2024.
144 funds tracked by Wall St. Rank held 89bio as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.